Response to Mylius et al

Timothy Lawn¹, Katarina Rukavina^{2

3}, Marzia Malcangio⁴, Matthew Howard¹, K Ray Chaudhuri^{2

3}

Affiliations

¹ Department of Neuroimaging, The Institute of Psychiatry, Psychology, and Neuroscience, King's College London.
² The Maurice Wohl Clinical Neuroscience Institute, The Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom.
³ Parkinson Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
⁴ Wolfson Centre for Age Related Diseases, The Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom.

Comment

Timothy Lawn et al. Pain. 2022.

. 2022 Mar 1;163(3):e496-e497.

doi: 10.1097/j.pain.0000000000002445.

Timothy Lawn¹, Katarina Rukavina^{2

3}, Marzia Malcangio⁴, Matthew Howard¹, K Ray Chaudhuri^{2

3}

¹ Department of Neuroimaging, The Institute of Psychiatry, Psychology, and Neuroscience, King's College London.
² The Maurice Wohl Clinical Neuroscience Institute, The Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom.
³ Parkinson Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
⁴ Wolfson Centre for Age Related Diseases, The Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom.

No abstract available

Comment on

Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease.
Lawn T, Aman Y, Rukavina K, Sideris-Lampretsas G, Howard M, Ballard C, Ray Chaudhuri K, Malcangio M. Lawn T, et al. Pain. 2021 Apr 1;162(4):999-1006. doi: 10.1097/j.pain.0000000000002111. Pain. 2021. PMID: 33239526 Free PMC article. No abstract available.
On the diagnosis of pain in Parkinson disease: a mechanism-based approach.
Mylius V, Perez Lloret S, Ciampi de Andrade D. Mylius V, et al. Pain. 2022 Mar 1;163(3):e495-e496. doi: 10.1097/j.pain.0000000000002446. Pain. 2022. PMID: 35148288 No abstract available.

1. Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-Pecurariu C, Kessel B, Silverdale M, Todorova A, Sauerbier A, Odin P, Antonini A, Martinez-Martin P; EUROPAR and the IPMDS Non Motor PD Study Group. King's Parkinson's disease pain scale, the first scale for pain in PD: an international validation. Mov Disord 2015;30:1623–31.
1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464–74.
1. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. PAIN 2014;155:2263–73.
1. Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, Hansson P, Haroutounian S, Arendt-Nielsen L, Attal N, Baron R, Brell J, Bujanover S, Burke LB, Carr D, Chappell AS, Cowan P, Etropolski M, Fillingim RB, Gewandter JS, Katz NP, Kopecky EA, Markman JD, Nomikos G, Porter L, Rappaport BA, Rice ASC, Scavone JM, Scholz J, Simon LS, Smith SM, Tobias J, Tockarshewsky T, Veasley C, Versavel M, Wasan AD, Wen W, Yarnitsky D. Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. PAIN 2016;157:1851–71.
1. Ford B. Pain in Parkinson's disease. Mov Disord 2010;25:S98–S103.